BAM
AST

Brave Asset Management’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Brave Asset Management’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-393
Closed -$3K – 457
2015
Q1 		$3K Hold
393
– – ﹤0.01% 409
2014
Q4 		$1K Buy
+393
New +$1.58K ﹤0.01% 433

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Brave Asset Management's AST Position: Q2 2015 in Review

Brave Asset Management sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q2 2015, closing a stake of 393 shares — an estimated $3K sold.

Brave Asset Management first reported a position in AST in Q4 2014 and held it in 2 quarters. The position peaked at $3K in Q1 2015. 63 funds tracked by Wall St. Rank hold AST as of Q2 2015.

  • Brave Asset Management reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q2 2015 after selling out during the quarter.
  • Brave Asset Management sold 393 Asterias Biotherapeutics Inc. Series A shares in Q2 2015, an estimated $3K.
  • Brave Asset Management first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 2 quarters.
  • Brave Asset Management's Asterias Biotherapeutics Inc. Series A position peaked at $3K in Q1 2015.
  • 63 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q2 2015.

Based on Brave Asset Management's 13F filing for Q2 2015, filed 11 Aug 2015.